microRNA information: hsa-miR-708-5p
Section | ID | link |
---|---|---|
Mature name: | hsa-miR-708-5p | miRbase |
Accession: | MIMAT0004926 | miRbase |
Precursor name: | hsa-mir-708 | miRbase |
Precursor accession: | MI0005543 | miRbase |
Symbol: | MIR708 | HGNC |
RefSeq ID: | NR_030598 | GenBank |
Sequence: | AAGGAGCUUACAAUCUAGCUGGG |
Reported expression in cancers: hsa-miR-708-5p
miRNA | cancer | regulation | reporting | PUBMED | method |
---|---|---|---|---|---|
hsa-miR-708-5p | breast cancer | deregulation | "Next-generation sequencing evaluated miR expressio ......" | 26124344 | RNA-Seq; Reverse transcription PCR |
hsa-miR-708-5p | colorectal cancer | upregulation | "miR-708 and miR-31 were found to be highly express ......" | 25202407 | |
hsa-miR-708-5p | liver cancer | downregulation | "MicroRNA 708 is downregulated in hepatocellular ca ......" | 26211597 | Reverse transcription PCR; qPCR |
hsa-miR-708-5p | lung cancer | upregulation | "Increased miR 708 expression in NSCLC and its asso ......" | 22573352 | |
hsa-miR-708-5p | lymphoma | deregulation | "We identified an miRNA signature of 7 miRNAs 5 upr ......" | 23801630 | |
hsa-miR-708-5p | prostate cancer | upregulation | "Metformin induces ER stress dependent apoptosis th ......" | 26075749 |
Reported cancer pathway affected by hsa-miR-708-5p
miRNA | cancer | pathway | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-708-5p | bladder cancer | Apoptosis pathway | "Bladder cancer cell lines were exposed to normoxic ......" | 26196183 | Flow cytometry |
hsa-miR-708-5p | colorectal cancer | Apoptosis pathway | "Regulatory roles of microRNA 708 and microRNA 31 i ......" | 25202407 | |
hsa-miR-708-5p | glioblastoma | Apoptosis pathway | "miR 708 acts as a tumor suppressor in human gliobl ......" | 23754151 | |
hsa-miR-708-5p | prostate cancer | Apoptosis pathway | "Metformin induces ER stress dependent apoptosis th ......" | 26075749 |
Reported cancer prognosis affected by hsa-miR-708-5p
miRNA | cancer | prognosis | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-708-5p | liver cancer | progression; tumorigenesis; staging; metastasis | "MicroRNA 708 is downregulated in hepatocellular ca ......" | 26211597 | |
hsa-miR-708-5p | lung cancer | poor survival; staging | "Increased miR 708 expression in NSCLC and its asso ......" | 22573352 | |
hsa-miR-708-5p | lung squamous cell cancer | staging | "This study contained three phases: 1 marker discov ......" | 20526284 | |
hsa-miR-708-5p | ovarian cancer | metastasis; cell migration; poor survival | "Glucocorticoids mediate induction of microRNA 708 ......" | 25569036 | |
hsa-miR-708-5p | prostate cancer | worse prognosis; progression; poor survival; recurrence | "In this study we report that miR-708 is a key nega ......" | 22552290 | |
hsa-miR-708-5p | prostate cancer | drug resistance; staging | "Metformin induces ER stress dependent apoptosis th ......" | 26075749 |
Reported gene related to hsa-miR-708-5p
miRNA | cancer | gene | reporting | PUBMED |
---|---|---|---|---|
hsa-miR-708-5p | prostate cancer | AKT2 | "Together our findings suggest that reduced miR-708 ......" | 22552290 |
hsa-miR-708-5p | prostate cancer | CD44 | "Together our findings suggest that reduced miR-708 ......" | 22552290 |
hsa-miR-708-5p | colorectal cancer | CDKN2B | "In addition the CDKN2B protein levels were signifi ......" | 25202407 |
hsa-miR-708-5p | breast cancer | KDM1A | "miR-708 could directly target the LSD1 3'UTR to do ......" | 26833707 |
hsa-miR-708-5p | prostate cancer | NNAT | "Metformin promotes increased expression of miR-708 ......" | 26075749 |
hsa-miR-708-5p | ovarian cancer | RAP1B | "Glucocorticoids mediate induction of microRNA 708 ......" | 25569036 |
hsa-miR-708-5p | lung cancer | TMEM88 | "The transcript for TMEM88 gene has a miR-708 bindi ......" | 22573352 |
Expression profile in cancer corhorts:
Putative target regulations
miRNA | Gene | Cancer | Interaction | Correlation beta |
---|---|---|---|---|
hsa-miR-708-5p | RANBP2 | 11 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; LUAD; PAAD; PRAD; STAD; UCEC | miRNAWalker2 validate; MirTarget | TCGA BLCA -0.055; TCGA CESC -0.077; TCGA COAD -0.112; TCGA ESCA -0.081; TCGA HNSC -0.111; TCGA KIRC -0.087; TCGA LUAD -0.084; TCGA PAAD -0.113; TCGA PRAD -0.073; TCGA STAD -0.079; TCGA UCEC -0.066 |
hsa-miR-708-5p | EIF4E3 | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRP; LUAD; LUSC; PAAD; PRAD; STAD | MirTarget | TCGA BLCA -0.097; TCGA BRCA -0.059; TCGA ESCA -0.087; TCGA HNSC -0.255; TCGA KIRP -0.074; TCGA LUAD -0.119; TCGA LUSC -0.36; TCGA PAAD -0.105; TCGA PRAD -0.112; TCGA STAD -0.207 |
hsa-miR-708-5p | MASP1 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUAD; LUSC; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.319; TCGA BRCA -0.312; TCGA COAD -0.472; TCGA ESCA -0.24; TCGA HNSC -0.197; TCGA LUAD -0.549; TCGA LUSC -0.558; TCGA PRAD -0.367; TCGA STAD -0.352; TCGA UCEC -0.171 |
hsa-miR-708-5p | AFF4 | 11 cancers: BLCA; CESC; COAD; HNSC; KIRP; LGG; LUAD; LUSC; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.086; TCGA CESC -0.083; TCGA COAD -0.093; TCGA HNSC -0.196; TCGA KIRP -0.082; TCGA LGG -0.08; TCGA LUAD -0.105; TCGA LUSC -0.123; TCGA PRAD -0.125; TCGA STAD -0.098; TCGA UCEC -0.07 |
hsa-miR-708-5p | BBX | 10 cancers: BLCA; CESC; COAD; HNSC; KIRC; KIRP; LUAD; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.08; TCGA CESC -0.083; TCGA COAD -0.085; TCGA HNSC -0.1; TCGA KIRC -0.072; TCGA KIRP -0.095; TCGA LUAD -0.087; TCGA PRAD -0.221; TCGA STAD -0.078; TCGA UCEC -0.07 |
hsa-miR-708-5p | STARD8 | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRC; LUAD; LUSC; PRAD; THCA; UCEC | MirTarget | TCGA BLCA -0.112; TCGA CESC -0.118; TCGA ESCA -0.181; TCGA HNSC -0.292; TCGA KIRC -0.067; TCGA LUAD -0.187; TCGA LUSC -0.545; TCGA PRAD -0.295; TCGA THCA -0.122; TCGA UCEC -0.125 |
hsa-miR-708-5p | NFE2L2 | 10 cancers: BLCA; COAD; KIRC; KIRP; LUAD; OV; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.09; TCGA COAD -0.066; TCGA KIRC -0.05; TCGA KIRP -0.073; TCGA LUAD -0.073; TCGA OV -0.073; TCGA PRAD -0.16; TCGA SARC -0.086; TCGA STAD -0.1; TCGA UCEC -0.067 |
hsa-miR-708-5p | SARM1 | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRP; LGG; LUAD; PAAD; STAD | MirTarget | TCGA BLCA -0.135; TCGA BRCA -0.079; TCGA CESC -0.261; TCGA ESCA -0.292; TCGA HNSC -0.111; TCGA KIRP -0.077; TCGA LGG -0.106; TCGA LUAD -0.103; TCGA PAAD -0.151; TCGA STAD -0.081 |
hsa-miR-708-5p | MPL | 13 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; OV; PAAD; PRAD; STAD | MirTarget | TCGA BLCA -0.091; TCGA BRCA -0.088; TCGA CESC -0.075; TCGA ESCA -0.116; TCGA HNSC -0.17; TCGA KIRC -0.083; TCGA KIRP -0.101; TCGA LUAD -0.125; TCGA LUSC -0.139; TCGA OV -0.069; TCGA PAAD -0.166; TCGA PRAD -0.147; TCGA STAD -0.161 |
hsa-miR-708-5p | PXK | 12 cancers: BLCA; CESC; ESCA; HNSC; KIRC; LUAD; LUSC; OV; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.128; TCGA CESC -0.099; TCGA ESCA -0.062; TCGA HNSC -0.218; TCGA KIRC -0.09; TCGA LUAD -0.106; TCGA LUSC -0.172; TCGA OV -0.077; TCGA PRAD -0.115; TCGA SARC -0.077; TCGA STAD -0.091; TCGA UCEC -0.065 |
hsa-miR-708-5p | TRIM23 | 10 cancers: BLCA; BRCA; CESC; HNSC; LGG; LUAD; LUSC; PRAD; SARC; UCEC | MirTarget | TCGA BLCA -0.084; TCGA BRCA -0.054; TCGA CESC -0.051; TCGA HNSC -0.134; TCGA LGG -0.133; TCGA LUAD -0.108; TCGA LUSC -0.146; TCGA PRAD -0.145; TCGA SARC -0.052; TCGA UCEC -0.052 |
hsa-miR-708-5p | FAM107A | 12 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.298; TCGA BRCA -0.133; TCGA ESCA -0.337; TCGA HNSC -0.594; TCGA KIRC -0.214; TCGA LUAD -0.48; TCGA LUSC -0.935; TCGA PAAD -0.273; TCGA PRAD -0.442; TCGA SARC -0.11; TCGA THCA -0.175; TCGA STAD -0.271 |
hsa-miR-708-5p | FEM1C | 9 cancers: BLCA; COAD; HNSC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.073; TCGA COAD -0.055; TCGA HNSC -0.077; TCGA LUAD -0.114; TCGA LUSC -0.1; TCGA PRAD -0.117; TCGA SARC -0.108; TCGA STAD -0.097; TCGA UCEC -0.073 |
hsa-miR-708-5p | SCUBE1 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUAD; LUSC; PAAD; PRAD; STAD | MirTarget | TCGA BLCA -0.234; TCGA BRCA -0.156; TCGA COAD -0.27; TCGA ESCA -0.57; TCGA HNSC -0.336; TCGA LUAD -0.512; TCGA LUSC -0.906; TCGA PAAD -0.289; TCGA PRAD -0.139; TCGA STAD -0.316 |
hsa-miR-708-5p | EFR3B | 10 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; PAAD; THCA | MirTarget | TCGA BLCA -0.089; TCGA CESC -0.159; TCGA HNSC -0.156; TCGA KIRC -0.152; TCGA KIRP -0.105; TCGA LGG -0.123; TCGA LUAD -0.156; TCGA LUSC -0.461; TCGA PAAD -0.19; TCGA THCA -0.191 |
hsa-miR-708-5p | TM4SF18 | 9 cancers: BLCA; COAD; ESCA; HNSC; LUSC; OV; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.076; TCGA COAD -0.127; TCGA ESCA -0.245; TCGA HNSC -0.224; TCGA LUSC -0.464; TCGA OV -0.078; TCGA SARC -0.079; TCGA THCA -0.215; TCGA UCEC -0.133 |
hsa-miR-708-5p | ETF1 | 9 cancers: BLCA; COAD; HNSC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.057; TCGA COAD -0.061; TCGA HNSC -0.069; TCGA LUAD -0.097; TCGA LUSC -0.054; TCGA PRAD -0.056; TCGA SARC -0.057; TCGA STAD -0.058; TCGA UCEC -0.062 |
hsa-miR-708-5p | AMIGO1 | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; LUAD; LUSC; PAAD; PRAD; STAD | MirTarget; miRNATAP | TCGA BLCA -0.078; TCGA BRCA -0.146; TCGA ESCA -0.251; TCGA HNSC -0.226; TCGA KIRC -0.1; TCGA LUAD -0.221; TCGA LUSC -0.201; TCGA PAAD -0.305; TCGA PRAD -0.182; TCGA STAD -0.262 |
hsa-miR-708-5p | EZH1 | 10 cancers: BLCA; BRCA; KIRC; KIRP; LUAD; LUSC; PAAD; PRAD; SARC; STAD | MirTarget | TCGA BLCA -0.085; TCGA BRCA -0.121; TCGA KIRC -0.078; TCGA KIRP -0.095; TCGA LUAD -0.102; TCGA LUSC -0.112; TCGA PAAD -0.072; TCGA PRAD -0.07; TCGA SARC -0.093; TCGA STAD -0.114 |
hsa-miR-708-5p | RHOBTB2 | 11 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LGG; LUAD; LUSC; PRAD; THCA; STAD | mirMAP | TCGA BLCA -0.122; TCGA BRCA -0.052; TCGA CESC -0.271; TCGA ESCA -0.178; TCGA HNSC -0.106; TCGA LGG -0.175; TCGA LUAD -0.242; TCGA LUSC -0.589; TCGA PRAD -0.148; TCGA THCA -0.088; TCGA STAD -0.068 |
hsa-miR-708-5p | PPP1R12B | 12 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LGG; LUAD; LUSC; PRAD; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.308; TCGA BRCA -0.105; TCGA COAD -0.154; TCGA ESCA -0.176; TCGA HNSC -0.315; TCGA LGG -0.076; TCGA LUAD -0.146; TCGA LUSC -0.266; TCGA PRAD -0.272; TCGA SARC -0.377; TCGA STAD -0.316; TCGA UCEC -0.108 |
hsa-miR-708-5p | TNS1 | 9 cancers: BLCA; CESC; HNSC; LGG; LUAD; LUSC; PRAD; SARC; STAD | mirMAP | TCGA BLCA -0.31; TCGA CESC -0.191; TCGA HNSC -0.331; TCGA LGG -0.075; TCGA LUAD -0.225; TCGA LUSC -0.488; TCGA PRAD -0.298; TCGA SARC -0.233; TCGA STAD -0.158 |
hsa-miR-708-5p | DUSP3 | 10 cancers: BLCA; CESC; ESCA; HNSC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.119; TCGA CESC -0.059; TCGA ESCA -0.087; TCGA HNSC -0.129; TCGA LUAD -0.092; TCGA LUSC -0.115; TCGA PRAD -0.162; TCGA SARC -0.145; TCGA STAD -0.138; TCGA UCEC -0.116 |
hsa-miR-708-5p | NFIC | 9 cancers: BLCA; BRCA; CESC; HNSC; LUAD; LUSC; PRAD; SARC; STAD | mirMAP | TCGA BLCA -0.157; TCGA BRCA -0.106; TCGA CESC -0.113; TCGA HNSC -0.331; TCGA LUAD -0.133; TCGA LUSC -0.077; TCGA PRAD -0.166; TCGA SARC -0.159; TCGA STAD -0.092 |
hsa-miR-708-5p | ADCY9 | 9 cancers: BLCA; BRCA; HNSC; LUAD; LUSC; PAAD; PRAD; SARC; THCA | mirMAP | TCGA BLCA -0.106; TCGA BRCA -0.066; TCGA HNSC -0.146; TCGA LUAD -0.194; TCGA LUSC -0.186; TCGA PAAD -0.113; TCGA PRAD -0.093; TCGA SARC -0.135; TCGA THCA -0.106 |
hsa-miR-708-5p | TOM1L2 | 11 cancers: BLCA; BRCA; HNSC; KIRC; LGG; LUAD; LUSC; PAAD; SARC; THCA; STAD | mirMAP | TCGA BLCA -0.082; TCGA BRCA -0.16; TCGA HNSC -0.136; TCGA KIRC -0.124; TCGA LGG -0.091; TCGA LUAD -0.161; TCGA LUSC -0.108; TCGA PAAD -0.192; TCGA SARC -0.13; TCGA THCA -0.088; TCGA STAD -0.136 |
hsa-miR-708-5p | STK40 | 9 cancers: BLCA; BRCA; ESCA; HNSC; LUAD; LUSC; PRAD; THCA; STAD | mirMAP | TCGA BLCA -0.077; TCGA BRCA -0.062; TCGA ESCA -0.116; TCGA HNSC -0.079; TCGA LUAD -0.06; TCGA LUSC -0.08; TCGA PRAD -0.057; TCGA THCA -0.075; TCGA STAD -0.071 |
hsa-miR-708-5p | LRP10 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUSC; PRAD; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.065; TCGA BRCA -0.069; TCGA COAD -0.125; TCGA ESCA -0.132; TCGA HNSC -0.158; TCGA LUSC -0.13; TCGA PRAD -0.053; TCGA SARC -0.066; TCGA STAD -0.062; TCGA UCEC -0.073 |
hsa-miR-708-5p | KIF13B | 11 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LUAD; LUSC; PRAD; STAD; UCEC | mirMAP | TCGA BLCA -0.117; TCGA BRCA -0.241; TCGA CESC -0.273; TCGA ESCA -0.471; TCGA HNSC -0.348; TCGA KIRC -0.175; TCGA LUAD -0.124; TCGA LUSC -0.354; TCGA PRAD -0.086; TCGA STAD -0.067; TCGA UCEC -0.202 |
hsa-miR-708-5p | FZD4 | 9 cancers: BLCA; CESC; ESCA; HNSC; KIRP; LGG; LUAD; LUSC; THCA | miRNATAP | TCGA BLCA -0.126; TCGA CESC -0.193; TCGA ESCA -0.287; TCGA HNSC -0.204; TCGA KIRP -0.08; TCGA LGG -0.051; TCGA LUAD -0.11; TCGA LUSC -0.461; TCGA THCA -0.114 |
hsa-miR-708-5p | GPM6A | 9 cancers: BLCA; BRCA; HNSC; LGG; LUAD; LUSC; PAAD; PRAD; STAD | miRNATAP | TCGA BLCA -0.289; TCGA BRCA -0.222; TCGA HNSC -0.506; TCGA LGG -0.091; TCGA LUAD -0.646; TCGA LUSC -1.206; TCGA PAAD -0.369; TCGA PRAD -0.439; TCGA STAD -0.299 |
hsa-miR-708-5p | ZC3H12B | 9 cancers: BLCA; ESCA; HNSC; KIRP; LGG; LUAD; LUSC; PRAD; STAD | miRNATAP | TCGA BLCA -0.109; TCGA ESCA -0.537; TCGA HNSC -0.11; TCGA KIRP -0.082; TCGA LGG -0.152; TCGA LUAD -0.126; TCGA LUSC -0.299; TCGA PRAD -0.201; TCGA STAD -0.141 |
hsa-miR-708-5p | RAP1A | 9 cancers: BLCA; COAD; HNSC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.097; TCGA COAD -0.057; TCGA HNSC -0.099; TCGA LUAD -0.074; TCGA LUSC -0.176; TCGA PRAD -0.123; TCGA SARC -0.152; TCGA STAD -0.161; TCGA UCEC -0.055 |
hsa-miR-708-5p | NDRG2 | 9 cancers: BLCA; BRCA; HNSC; KIRC; LUAD; OV; PAAD; PRAD; STAD | miRNATAP | TCGA BLCA -0.101; TCGA BRCA -0.168; TCGA HNSC -0.339; TCGA KIRC -0.216; TCGA LUAD -0.188; TCGA OV -0.187; TCGA PAAD -0.151; TCGA PRAD -0.281; TCGA STAD -0.243 |
hsa-miR-708-5p | ITGA10 | 10 cancers: BRCA; CESC; ESCA; HNSC; KIRC; LGG; LUAD; LUSC; THCA; STAD | MirTarget | TCGA BRCA -0.242; TCGA CESC -0.237; TCGA ESCA -0.207; TCGA HNSC -0.11; TCGA KIRC -0.132; TCGA LGG -0.118; TCGA LUAD -0.183; TCGA LUSC -0.476; TCGA THCA -0.119; TCGA STAD -0.086 |
hsa-miR-708-5p | PAFAH2 | 14 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; PAAD; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BRCA -0.066; TCGA CESC -0.1; TCGA COAD -0.075; TCGA ESCA -0.26; TCGA HNSC -0.145; TCGA KIRC -0.073; TCGA KIRP -0.066; TCGA LUAD -0.088; TCGA LUSC -0.15; TCGA PAAD -0.075; TCGA PRAD -0.094; TCGA THCA -0.111; TCGA STAD -0.065; TCGA UCEC -0.059 |
hsa-miR-708-5p | VAT1L | 9 cancers: CESC; COAD; ESCA; HNSC; LGG; LUSC; PRAD; STAD; UCEC | MirTarget | TCGA CESC -0.173; TCGA COAD -0.301; TCGA ESCA -0.45; TCGA HNSC -0.334; TCGA LGG -0.389; TCGA LUSC -0.234; TCGA PRAD -0.245; TCGA STAD -0.354; TCGA UCEC -0.188 |
hsa-miR-708-5p | SACM1L | 13 cancers: CESC; COAD; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | MirTarget | TCGA CESC -0.081; TCGA COAD -0.092; TCGA ESCA -0.106; TCGA HNSC -0.087; TCGA KIRC -0.099; TCGA KIRP -0.05; TCGA LUAD -0.142; TCGA LUSC -0.158; TCGA OV -0.051; TCGA PAAD -0.072; TCGA PRAD -0.071; TCGA STAD -0.072; TCGA UCEC -0.08 |
Enriched cancer pathways of putative targets